Navigation Links
Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial,Targeting System's Success in Mouse Model Reported in Cancer Cell

ung's team set out to address two obstacles to gene therapy for pancreatic cancer: lack of a targeted gene expression system that hits the cancer hard but spares normal tissue, and the need for an animal model that allows monitoring of tumor growth and metastasis without having to kill and dissect the animal.

They solved the monitoring problem by modifying two lines of pancreatic cancer to stably express firefly luciferace enzyme - the bioluminescent agent that lights up fireflies. This allowed live imaging of the mice to monitor cancer progression.

The researchers already had developed several components of the gene expression system. Led by first author Xiaoming Xie, Ph.D., a postdoctoral fellow and now instructor in Hung's department, the team used those components and pieces developed elsewhere to painstakingly build what became C-VISA-BikDD.

They used a gene-based targeting promoter called CCKAR known to be active in pancreatic cancer but not in healthy pancreatic tissue. The problem with pancreatic-cancer-specific gene promoters such as CCKAR, Hung says, is that they select narrowly for cancer cells but are not highly active once they get there. The success of gene therapy depends on efficient gene expression after delivery.

A system using a viral promoter such as CMV has the opposite problem: strong activity but indiscriminate delivery of the therapeutic gene to healthy tissue, which increases toxicity. The team's goal was to retain CCKAR's selectivity while boosting its activity to levels seen in CMV promoter-driven therapy.

To strengthen activity, the team added two key components: a regulatory gene sequence known as WPRE and the two-step transcriptional amplification system (TSTA) known to amplify activity of the prostate-specific antigen (PSA) promoter.

This enhanced C-VISA package increased gene activity levels by 67.6 percent to 287 percent over the CMV-driven therapy in three lines of pancreatic cancer. Lab exp
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
2. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
3. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
4. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
5. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
6. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
7. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
8. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
9. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
10. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
11. MediQuest Concludes Confirmatory Phase III Study of Raynaud’s Therapy
Post Your Comments:
(Date:10/22/2014)... and AUSTIN, Texas ... and PureMHC LLC today announced they have entered ... novel antibody-based immunotherapies designed to target cancers. ... phosphorylated peptides displayed on the surfaces of tumor ... tumor targets (PTTs), derived from proteins that play ...
(Date:10/22/2014)... , Oct. 22, 2014  AcelRx Pharmaceuticals, ... that results from the  IAP310 study have been ... (RAPM), a peer-reviewed journal with broad, multidisciplinary ... trial evaluating the safety and efficacy of Zalviso, ... system (SSTS), for the treatment of post-operative pain ...
(Date:10/22/2014)... Calif. , Oct. 22, 2014 /PRNewswire/ ... ), a biopharmaceutical company leading the discovery ... today announced that it has demonstrated human ... ongoing clinical study evaluating RG-101, a wholly-owned, ... treatment of hepatitis C virus infection ("HCV").  ...
Breaking Medicine Technology:Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8
... YORK, Sept. 23 Reportlinker.com announces that a ... catalogue: Genzyme Corporation: PharmaVitae Profile ... Introduction This analysis examines the historical ... pharmaceutical sector. The profile encompasses global company strategy, ...
... Calif., Sept. 23 Preclinical data of a ... blood pressure) was presented Tuesday, September 21st, at ... Washington, DC, by Christopher D. Owens, MD, MSc, ... Endovascular Surgery, University of California, San Francisco. The ...
Cached Medicine Technology:Reportlinker Adds Genzyme Corporation: PharmaVitae Profile 2Reportlinker Adds Genzyme Corporation: PharmaVitae Profile 3Reportlinker Adds Genzyme Corporation: PharmaVitae Profile 4Reportlinker Adds Genzyme Corporation: PharmaVitae Profile 5Reportlinker Adds Genzyme Corporation: PharmaVitae Profile 6Reportlinker Adds Genzyme Corporation: PharmaVitae Profile 7Promising New Therapy for Drug-Resistant Hypertension Presented at Interventional Cardiology Meeting in Washington, D.C. 2
(Date:10/22/2014)... Shriners Hospitals for Children® and UK HealthCare have ... of Shriners Hospitals for Children - Lexington from 1900 ... of Kentucky Albert B. Chandler Hospital. The new facility ... operated by Shriners Hospitals for Children, and designed to ... families well into the future. , “The quality care ...
(Date:10/22/2014)... 22, 2014 Best Cheap Hosting USA ... world. The site has recently announced that iPower ( ... for people from around the world. , “iPower is ... today and is providing various kinds of useful products ... insists on offering excellent customer service and a number ...
(Date:10/22/2014)... King of Prussia, PA (PRWEB) October 22, 2014 ... Group, is recognized as an industry leader with over ... industry award winning team leader in the areas related ... In addition, Mr. Carlson is an Editorial Advisory Board ... Group Healthcare Council Educator. Blue Fin Group is ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 ... lead to increased blood pressure, according to a new study. ... blood pressure for young adult women or for teenagers, according ... lightly or moderately, their risk of high blood pressure was ... studies in older adult men and women," said lead researcher ...
(Date:10/20/2014)... Texas (PRWEB) October 20, 2014 The ... the must-have source of thousands of facts, figures and ... countries and 68 medical sector forecast categories the ... with global, regional and national views on the worldwide ... outlook. , The report gives you data for 2010-2019, ...
Breaking Medicine News(10 mins):Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4
... physicians for outpatient surgeries for bladder cancer have led ... procedures being performed and an overall increase in cost ... a new study published early online in Cancer ... The findings indicate that some Medicare policies aimed at ...
... the risk of developing asthma after the menopause, suggests a ... Thorax . The authors base their findings on ... HRT and development of asthma symptoms every two years between ... in the French E3N study, which includes almost 100, 000 ...
... ... ‘state-of-the-art’ building , ... Vancouver, Washington (PRWEB) February 7, 2010 -- Safetec Compliance Systems, Inc. ... Washington, effective immediately. The new office is located at 7700 NE Parkway Drive, ...
... ... culture, customs, history and music will open Feb. 28th in the St. Louis Jewish Community ... St. Louis, MO ... for Purim, an annual Jewish observance. The new museum is located inside the St. Louis ...
... , , Physician Assistant Foundation, Baylor College ... , HOUSTON , Feb. 6 The ... other local partners today unveiled their unique approach to providing health ... with hopes the program could become a model for meeting similar ...
... ... lift at his practice offering plastic surgery in Phoenix . For women who are ... popularity of cosmetic enhancement with breast implants. , ... Phoenix, AZ (Vocus) February 6, 2010 -- Over the course of his ...
Cached Medicine News:Health News:Medicare reimbursement change meant to save money has opposite effect 2Health News:Estrogen-only HRT may increase risk of asthma after menopause 2Health News:Safetec Compliance Systems Announces Expansion 2Health News:Community Health Navigator Program to Fill Gaps in Care for Houston's Burmese Refugees 2Health News:Community Health Navigator Program to Fill Gaps in Care for Houston's Burmese Refugees 3Health News:Community Health Navigator Program to Fill Gaps in Care for Houston's Burmese Refugees 4Health News:Is Breast Augmentation Surgery Right for Me? Arizona Breast Surgeon Discusses Various Breast Procedures 2Health News:Is Breast Augmentation Surgery Right for Me? Arizona Breast Surgeon Discusses Various Breast Procedures 3
... microscopic documentation. The Leica DC480 digital camera ... fidelity, resolution and detail. Even with low ... to perfect images due to the integrated ... modes make this camera the best choice ...
Coolpix 5000 microscope package includes Coolpix 5000 digital camera, MDC-A relay lens, EH52 AC adapter, UR-E6 step-down adapter ring, EU-1 wired remote control unit....
... Geometric Data Hemastainer. Formulated to ... quality control tested on human ... staining and absence of precipitate. ... a minimum of eight hours ...
Wright Stain Solutions...
Medicine Products: